Is Immunomedics Breast Cancer Treatment Doomed After This FDA Update?

Health and Healthcare

Published: January 18, 2019 9:50 am

Last Updated: January 31, 2020 1:49 am

Immunomedics Inc. (NASDAQ: IMMU) shares were crushed on Friday after the firm received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA). Usually, CRLs can spell disaster for a firm, and it takes a long time, as well as positive results, to fix this issue.

Specifically, the FDA issued a CRL for Immunomedics’ Biologics License Application (BLA) seeking accelerated approval of sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease.

For some quick background: Immunomedics develops monoclonal antibody-based products for the targeted treatment of cancer. Also, sacituzumab govitecan is a key part of this firm’s pipeline.

Prior to the reaction from shareholders, this company had a market cap of $3.4 billion. Now its market cap is closer to $2.3 billion. While this reaction isn’t affecting the cash holdings of the firm, it will make it more difficult for Immunomedics to progress.

Michael Pehl, president and CEO of Immunomedics, commented:

We believe in sacituzumab govitecan’s potential to be a viable treatment option for these patients. The issues related to approvability in the CRL were exclusively focused on Chemistry, Manufacturing and Control matters and no new clinical or preclinical data need to be generated. We are going to request a meeting with the FDA as soon as possible to gain a full understanding of the Agency’s requirements and timelines for approval and we will work closely with the FDA with the goal of bringing this important medicine to patients as soon as possible.

Shares of Immunomedics were last seen down 33% at $12.11, with a 52-week range of $12.86 to $27.33. The stock has a consensus analyst price target of $37.38.

24/7 Wall St.
Jefferies Has 4 Incredibly Cheap Stocks to Buy With Huge Growth Potential

The Average American Is Losing Momentum On Their Savings Every Day (Sponsor)

If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4%¹ today. Checking accounts are even worse.

But there is good news. To win qualified customers, some accounts are paying more than 7x the national average. That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn a $200 bonus and up to 7X the national average with qualifying deposits. Terms apply. Member, FDIC.

Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.

¹https://www.fdic.gov/national-rates-and-rate-caps